Capricor Therapeutics Inc (CAPR) concluded trading on Thursday at a closing price of $14.36, with 3.31 million shares of worth about $47.6 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 182.68% during that period and on March 20, 2025 the price saw a gain of about 17.51%. Currently the company’s common shares owned by public are about 40.33M shares, out of which, 39.94M shares are available for trading.
Stock saw a price change of 12.28% in past 5 days and over the past one month there was a price change of -4.84%. Year-to-date (YTD), CAPR shares are showing a performance of 4.06% which increased to 112.43% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.52 but also hit the highest price of $23.40 during that period. The average intraday trading volume for Capricor Therapeutics Inc shares is 1.15 million. The stock is currently trading 5.99% above its 20-day simple moving average (SMA20), while that difference is up 2.33% for SMA50 and it goes to 25.84% higher than SMA200.
Capricor Therapeutics Inc (NASDAQ: CAPR) currently have 40.33M outstanding shares and institutions hold larger chunk of about 39.05% of that.
The stock has a current market capitalization of $652.95M and its 3Y-monthly beta is at 4.60. It has posted earnings per share of -$1.06 in the same period. It has Quick Ratio of 4.19 while making debt-to-equity ratio of 0.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CAPR, volatility over the week remained 10.77% while standing at 10.75% over the month.
Stock’s fiscal year EPS is expected to rise by 34.04% while it is estimated to increase by 105.01% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Sandler on October 21, 2024 offering an Overweight rating for the stock and assigned a target price of $35 to it. Coverage by Oppenheimer stated Capricor Therapeutics Inc (CAPR) stock as an Outperform in their note to investors on May 17, 2024, suggesting a price target of $14 for the stock. On January 05, 2024, Cantor Fitzgerald Initiated their recommendations, while on October 26, 2022, Ladenburg Thalmann Initiated their ratings for the stock with a price target of $15. Stock get a Hold rating from Maxim Group on December 26, 2018.
